All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @dr.t__np on TikTok · 147s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @dr.t__np's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi, PSA and testosterone replacement therapy. Let's talk about it. So I get this question a lot and you need to ask yourself
  2. 0:06What does hi PSA mean? It means your PSA is high. That's it
  3. 0:12It doesn't mean cancer. I'd say 99% of the time
  4. 0:15It means that you have an enlarged prostate which for a man is an expected
  5. 0:19finding
  6. 0:20Just like hypertension and arthritis. These are expected findings with aging. I see hi PSA is all the time every time I do your labs
  7. 0:28I always check PSA and in three years of doing this and speaking to over
  8. 0:3316,000 men, I'll tell you what I find a high PSA in an older man
  9. 0:38Usually is prostatitis or BPH which stands for benign prosthetic hypertrophy
  10. 0:43That's a big fancy long name for an enlarged prostate
  11. 0:47Prostatitis is cleared up with antibiotics and if your PSA is high will go send you to urology and you'll have an MRI
  12. 0:55That is the gold standard for figuring out why your PSA is high
  13. 0:59Not a biopsy
  14. 1:01Biopsies are only about 47% accurate for diagnosing cancer the AUA or the American urological Association
  15. 1:09Actually recommends an MRI that is about 97 98% effective my younger guys that have high PSA usually it's a UTI or an STD
  16. 1:19PSA can also spike from sexual activity
  17. 1:22riding a motorcycle sitting in a 18 wheeler because that's your job
  18. 1:27Riding a stationary bike
  19. 1:29Vigorous exercise all these things can spike PSA. So when I do catch a high PSA the first thing I do. Let's just repeat it
  20. 1:36Labs make mistakes
  21. 1:39When we do repeat it, I'll ask you to please refrain from any of those things I just listed for 72 hours
  22. 1:46Also, if you're placing things up your rectum none of my business and all of yours
  23. 1:50But that will also make PSA spikes
  24. 1:52You need to refrain from those things too before we repeat your labs
  25. 1:55And if it's still high then you need to go see a urologist and schedule an MRI
  26. 2:0099% of the time this is a blip on the screen and we can fix it
  27. 2:04So don't panic when you see a higher PSA or a PSA that spikes some people this is just who they are and that's okay
  28. 2:10I hope this makes sense
  29. 2:12I hope you learned something today again
  30. 2:14If you'd like some more information about starting with me at my clinic
  31. 2:17Here's my website you can drop a comment under this post if you live in the US in one of the 50 states and on a telephone
  32. 2:23You can be my patient already on testosterone have no fear we take transfers to

@dr.t__np's PSA claims for TRT patients, fact-checked

Dr. T__NP

TikTok creator

42.4K viewsWatch on TikTok

Quick answer

PSA elevation in men on testosterone replacement therapy is a common clinical finding that requires systematic evaluation, including repeat testing after eliminating confounders and urology referral if values remain elevated. While mpMRI has become a preferred pre-biopsy tool per AUA 2023 guidelines, the creator's specific accuracy figures for both MRI and biopsy are oversimplified and not directly sourced from landmark trials. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in prostate cancer incidence with testosterone therapy versus placebo, which provides some reassurance but does not eliminate the need for routine PSA monitoring.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @dr.t__np's PSA claims for TRT patients, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@dr.t__np's PSA claims for TRT patients, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@dr.t__np's PSA claims for TRT patients, fact-checked" from Dr. T__NP. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: PSA elevation in men on testosterone replacement therapy is a common clinical finding that requires systematic evaluation, including repeat testing after eliminating confounders and urology referral if values remain elevated.

The reason this review is not generic is the source wording and the canonical claim label "trt what does a high psa really mean." In this clip, the useful excerpt is: "Hi, PSA and testosterone replacement therapy." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The PRECISION trial (2018, NEJM) found mpMRI-targeted biopsy detected 38% more clinically significant cancers than standard biopsy, supporting MRI as a preferred pre-biopsy tool, but its sensitivity is 74-93%, not 97-98%.
People who land here are usually trying to understand whether the Testosterone claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

PSA elevation in men on testosterone replacement therapy is a common clinical finding that requires systematic evaluation, including repeat testing after eliminating confounders and urology referral if values remain elevated.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • PSA elevation in men on testosterone replacement therapy is a common clinical finding that requires systematic evaluation, including repeat testing after eliminating confounders and urology referral if values remain elevated. While mpMRI has become a preferred pre-biopsy tool per AUA 2023 guidelines, the creator's specific accuracy figures for both MRI and biopsy are oversimplified and not directly sourced from landmark trials. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant increase in prostate cancer incidence with testosterone therapy versus placebo, which provides some reassurance but does not eliminate the need for routine PSA monitoring.
  • Among men with PSA between 4-10 ng/mL, roughly 25% will have prostate cancer detected on biopsy (Catalona et al., 1994, JAMA), making a blanket '99% benign' statement statistically inaccurate.
  • The PRECISION trial (2018, NEJM) found mpMRI-targeted biopsy detected 38% more clinically significant cancers than standard biopsy, supporting MRI as a preferred pre-biopsy tool, but its sensitivity is 74-93%, not 97-98%.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Among men with PSA between 4-10 ng/mL, roughly 25% will have prostate cancer detected on biopsy (Catalona et al., 1994, JAMA), making a blanket '99% benign' statement statistically inaccurate.
  • The PRECISION trial (2018, NEJM) found mpMRI-targeted biopsy detected 38% more clinically significant cancers than standard biopsy, supporting MRI as a preferred pre-biopsy tool, but its sensitivity is 74-93%, not 97-98%.
  • The TRAVERSE trial (Lincoff et al., 2023, NEJM) found testosterone therapy did not significantly increase prostate cancer incidence versus placebo, but PSA monitoring before and during TRT remains standard of care.
  • AUA 2023 guidelines recommend repeat PSA testing after eliminating confounders (exercise, ejaculation, prostate stimulation) before escalating to imaging or biopsy, consistent with what the creator advises.
  • The creator incorrectly names BPH as 'benign prosthetic hypertrophy.' The correct term is benign prostatic hyperplasia. This is a minor but factual error in a high-view medical video.
  • PSA alone is a poor single-test cancer detector. PSA density, free-to-total PSA ratio, and clinical history all inform risk stratification before any biopsy or imaging decision is made.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @dr.t__np actually say?

The creator, presenting as a nurse practitioner running a TRT clinic, made several specific claims about PSA elevation: that high PSA "doesn't mean cancer" and is "99% of the time" benign, that MRI is "97-98% effective" and is the gold standard over biopsy, that biopsies are only "about 47% accurate," and that common activities like riding a motorcycle or sexual activity can spike PSA. They also said prostatitis and BPH are the usual culprits in older men on TRT.

These claims are a mix of genuinely good reassurance and some numbers that deserve scrutiny. The overall message, that a single elevated PSA is not a death sentence, is clinically reasonable. But the specific percentages the creator throws out are either unsourced or oversimplified in ways that could mislead patients.

Does the science back this up?

Partially, yes. The American Urological Association (AUA) does recommend multiparametric MRI (mpMRI) as a preferred diagnostic step before biopsy in many clinical scenarios, particularly for men with elevated PSA but no prior biopsy. The PRECISION trial (Kasivisvanathan et al., 2018, NEJM) found MRI-targeted biopsy detected more clinically significant cancers and fewer insignificant ones compared to standard biopsy. That is a real result.

But "97-98% effective" is not a number you will find cleanly attributed to prostate MRI in any landmark trial. MRI sensitivity for clinically significant prostate cancer is typically cited between 74-93% depending on the study and cancer grade (Weinreb et al., 2016, European Urology). The 47% biopsy accuracy figure also needs context. Standard 12-core systematic biopsy does have real limitations, but accuracy varies considerably based on PSA level, prostate volume, and cancer grade. Calling it flatly 47% accurate strips all that nuance away.

What did they get wrong (or right)?

Credit where it is due: the creator is right that a single high PSA should not trigger immediate panic or biopsy. Repeat testing after eliminating confounders, like sexual activity, vigorous exercise, or recent prostate manipulation, is standard practice. The AUA and the National Comprehensive Cancer Network (NCCN) both support this approach. The creator is also correct that prostatitis and BPH are common, often reversible causes of PSA elevation in men on TRT.

Where they went wrong is with the "99%" framing. PSA is a real cancer screening tool, and dismissing it that broadly is a problem. Among men with PSA between 4-10 ng/mL, approximately 25% will have prostate cancer on biopsy (Catalona et al., 1994, JAMA). That is not a trivial number to round down to 1%. The creator also describes BPH as "benign prosthetic hypertrophy," which is an error. The correct term is benign prostatic hyperplasia. A small slip, but worth noting in a video watched 42,000 times by men making decisions about their health.

What should you actually know?

PSA is not a binary cancer alarm, but it is not meaningless noise either. Elevated PSA in men on TRT deserves a systematic workup, not dismissal. Testosterone therapy itself does not appear to significantly raise PSA in most men with normal baseline levels, a finding supported by the TRAVERSE trial (Lincoff et al., 2023, NEJM), but men on TRT should still have baseline PSA checked before starting and monitored regularly.

If your PSA comes back elevated, your provider should first rule out confounders and repeat the test. If it stays elevated, referral to urology and consideration of mpMRI is appropriate per AUA 2023 guidelines. Biopsy is not automatically the next step, but it is also not as inaccurate as this video implies. Your urologist will factor in your PSA density, free-to-total PSA ratio, and MRI findings before recommending anything invasive. No TikTok, including this one, replaces that conversation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. T__NP · TikTok creator

42.4K views on this video

What does a high PSA really mean?

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about among men with psa between 4-10 ng/ml, roughly 25% will?

Among men with PSA between 4-10 ng/mL, roughly 25% will have prostate cancer detected on biopsy (Catalona et al., 1994, JAMA), making a blanket '99% benign' statement statistically inaccurate.

What does the video say about the precision trial (2018, nejm) found mpmri-targeted biopsy detected 38%?

The PRECISION trial (2018, NEJM) found mpMRI-targeted biopsy detected 38% more clinically significant cancers than standard biopsy, supporting MRI as a preferred pre-biopsy tool, but its sensitivity is 74-93%, not 97-98%.

What does the video say about the traverse trial (lincoff et al., 2023, nejm) found testosterone?

The TRAVERSE trial (Lincoff et al., 2023, NEJM) found testosterone therapy did not significantly increase prostate cancer incidence versus placebo, but PSA monitoring before and during TRT remains standard of care.

What does the video say about aua 2023 guidelines recommend repeat psa testing after eliminating confounders?

AUA 2023 guidelines recommend repeat PSA testing after eliminating confounders (exercise, ejaculation, prostate stimulation) before escalating to imaging or biopsy, consistent with what the creator advises.

What does the video say about the creator incorrectly names bph as 'benign prosthetic hypertrophy.' the?

The creator incorrectly names BPH as 'benign prosthetic hypertrophy.' The correct term is benign prostatic hyperplasia. This is a minor but factual error in a high-view medical video.

What does the video say about psa alone?

PSA alone is a poor single-test cancer detector. PSA density, free-to-total PSA ratio, and clinical history all inform risk stratification before any biopsy or imaging decision is made.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. T__NP, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.